open access

Vol 67, No 3 (2016)
Original papers
Published online: 2016-01-19
Submitted: 2015-06-11
Accepted: 2015-07-24
Get Citation

Age may determine the effect of hypolipidemic agents on plasma adipokine levels in patients with elevated low-density lipoprotein cholesterol levels

Robert Krysiak, Witold Żmuda, Bogdan Marek, Bogusław Okopień
DOI: 10.5603/EP.a2016.0019
·
Endokrynologia Polska 2016;67(3):271-276.

open access

Vol 67, No 3 (2016)
Original papers
Published online: 2016-01-19
Submitted: 2015-06-11
Accepted: 2015-07-24

Abstract

Introduction: Lipid-lowering agents affect adipose tissue function. No study has investigated the role of age in the effects of hypolipidaemic agents on plasma adipokines.

Material and methods: The study was a retrospective analysis of data of 65 hypercholesterolaemic patients treated for 90 days with simvastatin, ezetimibe, or simvastatin/ezetimibe combination therapy. Circulating levels of leptin, adiponectin, visfatin, and tumour necrosis factor alpha (TNF-alpha), as well as high-sensitivity C-reactive protein (hsCRP) were assessed separately for patients aged between 35 and 50 years and between 51 and 65 years, at the beginning and at the end of treatment.

Results: Patients in the age between 51 and 65 years had higher plasma levels of TNF-alpha and hsCRP, and lower plasma levels of adiponectin than patients aged between 35 and 50 years. In both age groups, simvastatin reduced plasma levels of hsCRP, leptin, visfatin, and TNF-alpha and increased circulating levels of adiponectin. This effect was particularly pronounced if simvastatin was administered in combination with ezetimibe. Ezetimibe alone increased plasma adiponectin and reduced plasma levels of leptin and hsCRP only in older adults. Irrespectively of age, ezetimibe administered alone did not affect visfatin and TNF-alpha. The effect of simvastatin on plasma hsCRP and the investigated adipokines did not differ between both groups. In turn, the effect of ezetimibe and simvastatin/ezetimibe combination therapy on leptin, adiponectin, and hsCRP was stronger in older than in younger adults.

Conclusions: Our results show that age may partially determine the effect of ezetimibe, but not of simvastatin, on adipose tissue function. (Endokrynol Pol 2016; 67 (3): 271–276)

Abstract

Introduction: Lipid-lowering agents affect adipose tissue function. No study has investigated the role of age in the effects of hypolipidaemic agents on plasma adipokines.

Material and methods: The study was a retrospective analysis of data of 65 hypercholesterolaemic patients treated for 90 days with simvastatin, ezetimibe, or simvastatin/ezetimibe combination therapy. Circulating levels of leptin, adiponectin, visfatin, and tumour necrosis factor alpha (TNF-alpha), as well as high-sensitivity C-reactive protein (hsCRP) were assessed separately for patients aged between 35 and 50 years and between 51 and 65 years, at the beginning and at the end of treatment.

Results: Patients in the age between 51 and 65 years had higher plasma levels of TNF-alpha and hsCRP, and lower plasma levels of adiponectin than patients aged between 35 and 50 years. In both age groups, simvastatin reduced plasma levels of hsCRP, leptin, visfatin, and TNF-alpha and increased circulating levels of adiponectin. This effect was particularly pronounced if simvastatin was administered in combination with ezetimibe. Ezetimibe alone increased plasma adiponectin and reduced plasma levels of leptin and hsCRP only in older adults. Irrespectively of age, ezetimibe administered alone did not affect visfatin and TNF-alpha. The effect of simvastatin on plasma hsCRP and the investigated adipokines did not differ between both groups. In turn, the effect of ezetimibe and simvastatin/ezetimibe combination therapy on leptin, adiponectin, and hsCRP was stronger in older than in younger adults.

Conclusions: Our results show that age may partially determine the effect of ezetimibe, but not of simvastatin, on adipose tissue function. (Endokrynol Pol 2016; 67 (3): 271–276)

Get Citation

Keywords

age; simvastatin; ezetimibe; hypercholesterolemia; leptin; adiponectin; visfatin; tumor necrosis factor-α (TNF-α)

About this article
Title

Age may determine the effect of hypolipidemic agents on plasma adipokine levels in patients with elevated low-density lipoprotein cholesterol levels

Journal

Endokrynologia Polska

Issue

Vol 67, No 3 (2016)

Pages

271-276

Published online

2016-01-19

DOI

10.5603/EP.a2016.0019

Bibliographic record

Endokrynologia Polska 2016;67(3):271-276.

Keywords

age
simvastatin
ezetimibe
hypercholesterolemia
leptin
adiponectin
visfatin
tumor necrosis factor-α (TNF-α)

Authors

Robert Krysiak
Witold Żmuda
Bogdan Marek
Bogusław Okopień

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl